AstraZeneca PLC (AZN) Key Metrics
AZN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $256.54B
- Enterprise value
- $290.01B
- P/E (TTM)
- 23.8 10-yr median 35.3
- Forward P/E
- 14.6
- PEG ratio
- 1.18
- Price / sales
- 4.2 10-yr median 4.5
- Price / book
- 5.2 10-yr median 5.8
- EV / EBITDA
- 14.2 10-yr median 16.5
- Dividend yield
- 1.93% $3.20 a year
- Beta
- 0.21
AZN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAZN valuation Price multiples at each fiscal year-end price.
AZN returns How much profit the business earns on the capital it uses.
AZN per-share figures Results divided by the shares outstanding at year-end.
AZN financial health Debt, liquidity and how easily interest is covered.
AZN efficiency & capital use Working capital cycle and where the cash goes.
AZN valuation history
AZN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AZN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AZN cash returned to shareholders
AZN price vs earnings per share
AZN key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $287.19B | $204.82B | $210.40B | $211.54B | $166.25B | $131.27B | $129.74B | $96.24B | $87.93B | $69.17B |
| Enterprise value | $311.15B | $229.40B | $233.16B | $234.44B | $190.54B | $143.66B | $141.75B | $109.67B | $101.18B | $80.08B |
| P/E ratio | 28.0 | 29.1 | 35.3 | 64.3 | — | 41.1 | 97.2 | 44.7 | 29.3 | 19.8 |
| Price / sales | 4.9 | 3.8 | 4.6 | 4.8 | 4.4 | 4.9 | 5.3 | 4.4 | 3.9 | 3.0 |
| Price / book | 5.9 | 5.0 | 5.4 | 5.7 | 4.2 | 8.4 | 9.9 | 7.7 | 5.9 | 4.7 |
| Price / free cash flow | 33.1 | 28.2 | 32.0 | 29.2 | 44.2 | 59.9 | 254.9 | 77.2 | 44.9 | 37.8 |
| Price / operating cash flow | 19.7 | 17.3 | 20.3 | 21.6 | 27.9 | 27.4 | 43.7 | 36.8 | 24.6 | 16.7 |
| EV / sales | 5.3 | 4.2 | 5.1 | 5.3 | 5.1 | 5.4 | 5.8 | 5.0 | 4.5 | 3.5 |
| EV / EBITDA | 15.7 | 14.9 | 17.4 | 25.8 | 37.3 | 17.8 | 21.1 | 15.4 | 15.3 | 11.0 |
| EV / free cash flow | 35.9 | 31.5 | 35.5 | 32.4 | 50.6 | 65.5 | 278.5 | 88.0 | 51.7 | 43.7 |
| Earnings yield | 3.6% | 3.4% | 2.8% | 1.6% | 0.1% | 2.4% | 1.0% | 2.2% | 3.4% | 5.1% |
| Free cash flow yield | 3.0% | 3.6% | 3.1% | 3.4% | 2.3% | 1.7% | 0.4% | 1.3% | 2.2% | 2.6% |
| Dividend yield | 1.7% | 2.3% | 2.1% | 2.1% | 2.3% | 2.7% | 2.8% | 3.6% | 4.0% | 5.1% |
| Shareholder yield (dividends + buybacks) | 2.0% | 2.3% | 2.1% | 2.1% | 2.3% | 2.7% | 2.8% | 3.6% | 4.0% | 5.1% |
| Share price at fiscal year-end | $183.86 | $131.04 | $134.70 | $135.60 | $116.50 | $99.98 | $99.72 | $75.96 | $69.40 | $54.64 |
| Per share | ||||||||||
| Revenue per share | $37.60 | $34.60 | $29.33 | $28.43 | $26.22 | $20.27 | $18.74 | $17.43 | $17.73 | $18.17 |
| Earnings per share | $6.57 | $4.50 | $3.81 | $2.11 | $0.08 | $2.43 | $1.03 | $1.70 | $2.37 | $2.76 |
| Operating cash flow per share | $9.33 | $7.59 | $6.62 | $6.29 | $4.18 | $3.65 | $2.28 | $2.07 | $2.82 | $3.27 |
| Free cash flow per share | $5.55 | $4.65 | $4.20 | $4.64 | $2.64 | $1.67 | $0.39 | $0.98 | $1.55 | $1.45 |
| Cash per share | $3.68 | $3.53 | $3.75 | $4.00 | $4.48 | $6.09 | $4.78 | $4.48 | $3.59 | $4.66 |
| Book value per share | $31.16 | $26.09 | $25.06 | $23.74 | $27.52 | $11.90 | $10.09 | $9.84 | $11.81 | $11.73 |
| Tangible book value per share | −$6.67 | −$11.14 | −$12.16 | −$14.16 | −$16.20 | −$13.08 | −$14.89 | −$16.73 | −$18.19 | −$19.27 |
| Dividends per share | $3.18 | $2.96 | $2.87 | $2.80 | $2.70 | $2.72 | $2.76 | $2.75 | $2.78 | $2.81 |
| Capex per share | $3.78 | $2.93 | $2.42 | $1.65 | $1.54 | $1.98 | $1.89 | $1.08 | $1.28 | $1.83 |
| Debt per share | $19.02 | $19.27 | $18.32 | $18.68 | $21.51 | $15.52 | $14.01 | $15.09 | $14.05 | $13.28 |
| Shares outstanding | 1.56B | 1.56B | 1.56B | 1.56B | 1.43B | 1.31B | 1.30B | 1.27B | 1.27B | 1.27B |
| Change in shares outstanding | −0.1% | +0.1% | +0.1% | +9.3% | +8.7% | +0.9% | +2.7% | 0.0% | +0.1% | +0.1% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 22.9% | 17.6% | 15.6% | 8.6% | 0.4% | 22.2% | 10.4% | 15.7% | 20.1% | 21.0% |
| Return on invested capital (ROIC) | 16.4% | 12.7% | 11.6% | 6.1% | 1.8% | 15.6% | 9.1% | 12.5% | 13.6% | 17.9% |
| Return on assets (ROA) | 9.4% | 6.9% | 6.0% | 3.3% | 0.1% | 5.0% | 2.2% | 3.5% | 4.8% | 5.7% |
| Return on tangible assets | 18.7% | 15.3% | 13.9% | 8.8% | 0.3% | 9.4% | 4.6% | 8.0% | 11.8% | 15.0% |
| Free cash flow margin | 14.8% | 13.5% | 14.3% | 16.3% | 10.1% | 8.2% | 2.1% | 5.6% | 8.7% | 8.0% |
| Income quality (OCF / net income) | 1.42 | 1.69 | 1.74 | 2.98 | 53.24 | 1.50 | 2.22 | 1.21 | 1.19 | 1.18 |
| Financial health | ||||||||||
| Total debt | $29.70B | $30.11B | $28.62B | $29.14B | $30.69B | $20.38B | $18.23B | $19.11B | $17.81B | $16.81B |
| Cash & short-term investments | $5.74B | $5.53B | $5.86B | $6.24B | $6.40B | $7.99B | $6.22B | $5.68B | $4.55B | $5.90B |
| Net debt | $23.96B | $24.59B | $22.76B | $22.90B | $24.29B | $12.39B | $12.01B | $13.43B | $13.25B | $10.91B |
| Debt / equity | 0.61 | 0.74 | 0.73 | 0.79 | 0.78 | 1.30 | 1.39 | 1.53 | 1.19 | 1.13 |
| Debt / assets | 0.26 | 0.29 | 0.28 | 0.30 | 0.29 | 0.31 | 0.30 | 0.32 | 0.28 | 0.27 |
| Net debt / EBITDA | 1.21 | 1.59 | 1.70 | 2.52 | 4.75 | 1.53 | 1.79 | 1.89 | 2.00 | 1.50 |
| Current ratio | 0.94 | 0.93 | 0.82 | 0.86 | 1.16 | 0.96 | 0.86 | 0.96 | 0.80 | 0.87 |
| Quick ratio | 0.72 | 0.74 | 0.64 | 0.68 | 0.76 | 0.76 | 0.68 | 0.78 | 0.62 | 0.72 |
| Interest coverage | 8.1 | 5.9 | 5.2 | 2.8 | 0.8 | 4.1 | 2.1 | 2.5 | 2.7 | 3.6 |
| Working capital | −$1.89B | −$2.04B | −$5.49B | −$3.70B | $3.65B | −$763.0M | −$2.55B | −$701.0M | −$3.23B | −$1.99B |
| Invested capital | $72.63B | $65.38B | $61.91B | $59.94B | $63.56B | $28.01B | $25.14B | $25.90B | $28.21B | $25.76B |
| Tangible asset value | −$10.37B | −$17.33B | −$18.97B | −$22.07B | −$23.10B | −$17.15B | −$17.91B | −$19.62B | −$21.37B | −$22.57B |
| Net current asset value | −$36.63B | −$37.34B | −$36.90B | −$36.83B | −$39.83B | −$31.55B | −$31.22B | −$31.02B | −$33.56B | −$32.59B |
| Graham number | $67.84 | $51.41 | $46.36 | $33.55 | $6.97 | $25.53 | $15.26 | $19.41 | $25.08 | $27.01 |
| Graham net-net per share | −$28.78 | −$29.79 | −$30.14 | −$28.17 | −$34.40 | −$28.06 | −$27.13 | −$29.39 | −$30.42 | −$29.11 |
| Capital allocation | ||||||||||
| Dividends paid | $4.97B | $4.63B | $4.48B | $4.36B | $3.86B | $3.57B | $3.59B | $3.48B | $3.52B | $3.56B |
| Share buybacks (net) | $719.7M | $43.0M | $0 | — | — | — | — | — | — | — |
| Dividend payout ratio | 48.5% | 65.8% | 75.2% | 132.7% | — | 111.8% | 269.1% | 161.7% | 117.3% | 101.8% |
| Dividends + buybacks / free cash flow | 65.6% | 64.2% | 68.2% | 60.3% | 102.5% | 162.9% | 705.7% | 279.4% | 179.7% | 194.5% |
| Capex / revenue | 10.1% | 8.5% | 8.2% | 5.8% | 5.9% | 9.8% | 10.1% | 6.2% | 7.2% | 10.1% |
| Capex / operating cash flow | 40.5% | 38.7% | 36.5% | 26.2% | 36.9% | 54.3% | 82.9% | 52.4% | 45.3% | 55.8% |
| Capex / depreciation | 1.03 | 0.91 | 0.77 | 0.49 | 0.34 | 0.83 | 0.65 | 0.37 | 0.53 | 0.98 |
| Stock-based compensation / revenue | — | — | 1.3% | 1.4% | 1.6% | 1.0% | 1.1% | — | — | — |
| R&D / revenue | 24.2% | 25.1% | 23.9% | 22.0% | 26.0% | 22.5% | 24.8% | 26.9% | 25.6% | 25.6% |
| SG&A / revenue | 34.9% | 37.4% | 39.8% | 40.5% | 40.5% | 44.7% | 49.2% | 49.7% | 45.6% | 40.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 82.1 | 66.3 | 70.1 | 71.3 | 67.2 | 72.3 | 59.1 | 47.9 | 43.7 | 57.3 |
| Days of inventory on hand | 203.3 | 191.5 | 223.4 | 201.5 | 190.9 | 248.6 | 225.6 | 219.1 | 226.9 | 198.0 |
| Days payables outstanding | 496.4 | 123.5 | 128.4 | 79.2 | 75.9 | 142.0 | 129.6 | 148.1 | 167.6 | 227.7 |
| Cash conversion cycle (days) | -211.0 | 134.3 | 165.2 | 193.7 | 182.2 | 178.8 | 155.1 | 118.9 | 103.1 | 27.5 |
| Receivables turnover | 4.45 | 5.51 | 5.21 | 5.12 | 5.43 | 5.05 | 6.18 | 7.62 | 8.34 | 6.38 |
| Payables turnover | 0.74 | 2.96 | 2.84 | 4.61 | 4.81 | 2.57 | 2.82 | 2.46 | 2.18 | 1.60 |
| Inventory turnover | 1.80 | 1.91 | 1.63 | 1.81 | 1.91 | 1.47 | 1.62 | 1.67 | 1.61 | 1.84 |
| Asset turnover | 0.54 | 0.53 | 0.46 | 0.44 | 0.43 | 0.42 | 0.40 | 0.36 | 0.36 | 0.38 |
| Average receivables | $13.21B | $9.82B | $8.80B | $8.66B | $6.89B | $5.27B | $3.95B | $2.90B | $2.69B | $3.61B |
| Average payables | $14.46B | $3.45B | $2.91B | $2.69B | $2.59B | $2.06B | $1.75B | $2.00B | $1.98B | $2.57B |
| Average inventory | $5.92B | $5.36B | $5.06B | $6.84B | $6.50B | $3.61B | $3.04B | $2.96B | $2.68B | $2.24B |
| Intangibles / total assets | 51.8% | 55.9% | 57.5% | 61.3% | 59.2% | 49.1% | 53.0% | 55.5% | 60.0% | 62.8% |
Computed from AZN's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AZN valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), AstraZeneca traded at 28.0 times earnings, against a 10-year median of 35.3. Based on the latest twelve months, the trailing P/E is 23.8 and the forward P/E is 14.6. AstraZeneca earned a return on equity of 22.9% and a return on invested capital of 16.4% in fiscal 2025. It ended the year with $29.7 billion of debt and $5.7 billion in cash and short-term investments, net debt of $24.0 billion. It returned $5.7 billion to shareholders: $5.0 billion in dividends and $719.7 million in share buybacks, 66% of free cash flow. The share count rose 23.4% from 1.27B to 1.56B over 9 years.
See the AZN income statement, the AZN chart for price history, or the AZN stock overview for the latest quote and news.
AZN key metrics FAQ
What is AstraZeneca's P/E ratio?
AstraZeneca's trailing P/E ratio is 23.8 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 14.6. At the end of fiscal 2025 it was 28.0, compared with a 10-year median of 35.3.
What is AstraZeneca's EV/EBITDA?
AstraZeneca's enterprise value was 15.7 times EBITDA at the end of fiscal 2025 (enterprise value $311.2 billion, EBITDA $19.8 billion); the current EV/EBITDA is 14.2.
What is AstraZeneca's return on equity?
AstraZeneca's return on equity (ROE) was 22.9% in fiscal 2025: net income of $10.3 billion on average shareholders' equity of $44.7 billion.
What is AstraZeneca's ROIC?
AstraZeneca's return on invested capital was 16.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does AstraZeneca have?
AstraZeneca had total debt of $29.7 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.61 and $24.0 billion of net debt (1.21 times EBITDA).
What is AstraZeneca's dividend yield?
AstraZeneca's forward dividend yield is 1.93%. AstraZeneca paid $5.0 billion in dividends in fiscal 2025 ($3.18 per share), a payout ratio of 48.5%.
Does AstraZeneca buy back its shares?
Yes. AstraZeneca spent $719.7 million on net share repurchases in fiscal 2025 Shares outstanding changed −0.1% over the year, to 1.56B..
What is AstraZeneca's free cash flow yield?
AstraZeneca generated $8.7 billion of free cash flow in fiscal 2025, a free cash flow yield of 3.0% on its market value at year-end ($287.2 billion).
What is AstraZeneca's current ratio?
AstraZeneca's current ratio was 0.94 at the end of fiscal 2025: current assets were 0.94 times current liabilities.